BioTuesdays

Category - Markets

Longbaord-Pharmaceuticals
Markets

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

April 6, 2021
EyeGate Pharmaceuticals
Markets

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

March 31, 2021
Lineage-Cell-Therapeutics-Logo
Markets

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

March 31, 2021
Amryt-Logo
Markets

Maxim starts Amryt Pharma at buy; PT $27

Maxim Group launched coverage of Amryt Pharma plc (NASDAQ, AIM:AMYT) with a “buy” rating and $27 price target. The stock closed at $13.84 on March 30. Amryt is a commercial rare disease company globally marketing...

March 31, 2021
CareRX-Logo
Markets

Echelon starts CareRx at buy; PT $7.25 (Canadian)

Echelon Capital Markets initiated coverage of CareRx (TSX:CRRX) with a “buy” rating and price target of $7.25 (Canadian). The stock closed at $5.39 on March 29. CareRx is Canada’s leading pharmacy services provider for...

March 30, 2021
Markets

Cantor starts PAVmed at OW; PT $8

Cantor Fitzgerald initiated coverage of PAVmed (NASDAQ:PAVM) with an “overweight” rating and price target of $8. The stock closed at $3.93 on March 29. The company employs a unique business model that emphasizes capital...

March 29, 2021
Aytu-Biosceince-logo
Markets

Cantor starts Aytu BioPharma at OW; PT $11

Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...

March 29, 2021